新型前列腺癌分级系统可预测Gleason评分8-10分前列腺癌术后长期生存
该研究纳入1984至2014年间接受根治性前列腺切除术的男性,其中穿刺Gleason评分8-10分者721例、根治标本Gleason评分8-10分者1047例,比较Gleason评分8分与9-10分者的全因死亡和前列腺癌特异性死亡风险,发现9-10分者风险更高,支持新型五级前列腺癌分级系统在术前和术后区分8分与9-10分。
要点
- 穿刺Gleason评分9-10分者前列腺癌特异性生存率显著低于8分者(HR 2.13)。
- 根治标本Gleason评分9-10分者前列腺癌特异性生存率显著低于8分者(HR 2.38)。
- 调整围手术期变量后,Gleason评分9-10分与更高死亡风险的关联持续存在。
核心结论
- Gleason评分9-10分男性较Gleason评分8分男性具有更高的全因死亡率和前列腺癌特异性死亡率。
- 作者认为,根据新型前列腺癌分级系统,术前和术后均应分别考虑Gleason评分8分与9-10分前列腺癌。
研究设计与样本
- 研究纳入1984年至2014年间接受根治性前列腺切除术的23918名男性,其中穿刺Gleason评分8-10分者721例,根治标本Gleason评分8-10分者1047例。
- 比较Gleason评分8分与9-10分男性的临床病理特征,采用Cox回归和竞争风险分析比较两组全因死亡和前列腺癌特异性死亡风险,并调整其他围手术期变量及以其他原因死亡为竞争事件。
主要发现
- 与Gleason评分8分男性相比,Gleason评分9-10分男性根治性前列腺切除术年份更晚且病理分期更高。
- 穿刺Gleason评分8-10分男性中115例死亡(82例死于前列腺癌),总生存和癌特异性生存的中位随访均为3年(四分位距1-7)。
- 根治标本Gleason评分8-10分男性中221例死亡(151例死于前列腺癌),总生存和癌特异性生存的中位随访分别为4年(四分位距2-8)和4年(四分位距2-9)。
- 穿刺Gleason评分9-10分男性较8分男性前列腺癌特异性生存率显著更低(HR 2.13,95%CI 1.37-3.30;p<0.01)。
- 根治标本Gleason评分9-10分男性较8分男性前列腺癌特异性生存率显著更低(HR 2.38,95%CI 1.74-3.28;p<0.01)。
关键数值与推荐
- 穿刺Gleason评分9-10分 vs 8分:前列腺癌特异性生存率显著更低,HR 2.13(95%CI 1.37-3.30;p<0.01)。
- 根治标本Gleason评分9-10分 vs 8分:前列腺癌特异性生存率显著更低,HR 2.38(95%CI 1.74-3.28;p<0.01)。
临床怎么用
- 作者认为,根据新型前列腺癌分级系统,术前和术后均应分别考虑Gleason评分8分与9-10分前列腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The newly proposed five-tiered prostate cancer grading system (PCGS) divides Gleason score (GS) 8-10 disease into GS 8 and GS 9-10 on the basis of biochemical recurrence (BCR) following radical prostatectomy (RP) as an outcome. However, BCR does not necessarily portend worse survival outcomes. OBJECTIVE: To assess the significance of distinguishing GS 8 versus 9-10 disease in terms of long-term survival outcomes for both the preoperative setting using biopsy (Bx) GS and the postoperative setting with RP GS. DESIGN, SETTING, AND PARTICIPANTS: Of 23918 men who underwent RP between 1984 and 2014, there were 721 men with biopsy GS 8-10, and 1047 men with RP GS 8-10. OUTCOME MEASURES AND STATISTICAL ANALYSIS: Clinicopathologic characteristics were compared between men with GS 8 and those with GS 9-10. We compared all-cause mortality (ACM) and prostate cancer-specific mortality (PCSM) risk between the groups using Cox regression and competing-risks analyses, adjusting for other perioperative variables and death from other causes as the competing event. RESULTS AND LIMITATIONS: Compared to men with GS 8, men with GS 9-10 had later RP year and higher pathologic stage. Among men with Bx GS 8-10, 115 died (82 due to PC) with median follow-up of 3 yr (interquartile range [IQR] 1-7) for both overall and cancer-specific survival. Of men with RP GS 8-10, 221 died (151 due to PC) with median follow-up of 4 yr (IQR 2-8) and 4 yr (IQR 2-9) for overall and cancer-specific survival, respectively. PC-specific survival rates were significantly lower for men with GS 9-10 compared to men with GS 8 for both Bx (hazard ratio [HR] 2.13, 95% confidence interval [CI] 1.37-3.30; p<0.01) and RP GS (HR 2.38, 95% CI 1.74-3.28; p<0.01). This association persisted in multivariable models after adjusting for perioperative variables. CONCLUSIONS: Men with GS 9-10 had higher ACM and PCSM rates compared to those with GS 8. GS 8 and GS 9-10 PC should be considered separately in both the preoperative and postoperative setting as suggested by the new PCGS. PATIENT SUMMARY: The prostate cancer grading system can predict mortality risk after radical prostatectomy (RP) for men with Gleason score 8-10 disease based on both biopsy and RP Gleason scores. There are significant differences in all-cause mortality and prostate cancer-specific mortality following surgery between men with Gleason score 8 and those with Gleason score 9-10 disease.
引用
- Ham WS, Chalfin HJ, Feng Z, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol. 2016. PMID: 27876305. doi:10.1016/j.eururo.2016.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。